Efficacy and Safety of All-Trans Retinoic Acid Combined with Decitabine for the Treatment of Refractory cancer treatment-induced Thrombocytopenia:a clinical study.

开始日期2025-03-31

申办/合作机构

Henan Provincial Cancer Hospital

ChiCTR2500099941

/ Completed临床1期IIT

A single-arm, exploratory clinical study of tricacilli in preventing myelosuppression induced by platinum-containing chemotherapy in advanced non-small cell lung cancer - A single-arm, exploratory clinical study of tricacilli in preventing myelosuppression induced by platinum-containing chemotherapy in advanced non-small cell lung cancer

开始日期2024-04-02

申办/合作机构

Henan Provincial Cancer Hospital

ChiCTR1800014953

/ Recruiting临床1期IIT

Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia

开始日期2018-02-24

申办/合作机构

Henan Provincial Cancer Hospital

100 项与 Henan Provincial Cancer Hospital 相关的临床结果

登录后查看更多信息

0 项与 Henan Provincial Cancer Hospital 相关的专利（医药）

登录后查看更多信息

项与 Henan Provincial Cancer Hospital 相关的文献（医药）

2025-02-01·Journal of Clinical Oncology

Current status of physicians’ perception of HCC conversion/downstaging therapy: A nationwide survey in China.

作者: Bi, Xinyu ; Sun, Hui-Chuan ; Xue, Jianfeng ; Tan, Guang ; Zhao, Hai-Tao ; Huang, Tao ; Zhao, Ming ; Chen, Jinzhang ; Cai, Jianqiang ; Liang, Xiao ; Zhu, Xiao-Dong

585Background: Conversion or downstaging therapy for intermediate and advanced unresectable hepatocellular carcinoma (HCC) has emerged as a significant exploring area of clinical practice and research in recent years. Nonetheless, there exists considerable variability in both the selection criteria for patients undergoing conversion therapy and the regimens selected for conversion across different regions and medical institutions. The present study aims to elucidate the current clinical application of conversion therapy in China, as well as to identify the considerations that physicians take into account when selecting eligible patients for conversion therapy and determining the appropriate conversion modality. Methods: Physicians meeting predefined inclusion criteria were invited to complete an online questionnaire from January to July, 2024. The collected data were subsequently pooled and analyzed descriptively. Results: A total of 120 valid questionnaires were retrieved, mainly form surgical (69.2%, n=83) and interventional (30.8%, n=37) departments. Generally, the study showed that approximately 51% of stage Ib-IIIa patients will be selected for the treatment goal of conversion or downstaging, and the overall successful rate as meeting criteria for surgical resection after treatment was 36%. Three primary factors were prioritized by physicians for determination of conversion therapy: the type of portal vein tumor thrombus (PVTT) (97%, 116/120), the future liver volume (90%, 108/120), and Child-Pugh classification (90%,108/120). In the specific physician group who selected the following attributes, patients classified as Child-Pugh A (82%, 89/108) or Child-Pugh B7 (66%, 71/108), those with tumor diameter exceeding 5 cm (92%, 98/106) and Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1 (89%, 76/85) were most frequently selected for conversion therapy. Additionally, study showed that patients presenting with Vp1-2 (72%, 83/116) and Vp3 (71%, 82/116) could also be considered for conversion therapy. Currently, the prevalent treatment approach of conversion therapy involves a combination of local and systemic therapies, which is utilized in approximately 73% of cases. Among systemic treatment methodologies, the combination of Lenvatinib and immunotherapy is the most widely adopted by physicians. Besides, higher ORR was the foremost consideration for 83% (99/120) of physicians, followed by rapid response (68%, 82/120), adherence to guidelines and consensus (63%, 76/120), and lower tumor progression rate (58%, 70/120). Conclusions: This study elucidates the current status of conversion therapy for HCC in China. The findings underscore the necessity for optimizing conversion modalities and advancing standardized practices in the application of conversion therapy.

2025-01-01·International Journal of Medical Sciences

A novel nomogram on predicting extrahepatic metastasis in colorectal cancer with liver metastasis for selective application of ¹⁸F-FDG PET/CT

Article

作者: Zhang, Bin ; Wang, Libo ; Zhu, Rongtao ; Wei, Sidong ; Zhao, Yipu ; Zhao, Jie

Background: A more accurate assessment of extrahepatic metastases (EHMs) with colorectal cancer liver metastases (CRLMs) improve patient prognosis without unnecessary surgery and economic burden. At present, PET-CT can only be used as a second-line modality. We aimed to construct a predictive model for EHMs, and provide guidance for the selective application of ¹⁸F-FDG PET/CT. Methods: The clinical data of patients with CRLMs between December 2018 and February 2023 were retrospectively retrieved from the medical records of three large-capacity hospitals. Moreover, we explored the need for ¹⁸F-FDG PET/CT to be used selectively for detecting EHMs with CRLMs. Results: A total of 471 patients from two hospitals were included in the training set, 174 of whom had CRLMs and EHMs. Notably, the percentages of patients with positive serum CEA, CA19-9 and CA-125 levels were significantly greater in patients with CRLMs and EHMs than in those with liver-limited metastases. Univariate and multivariate logistic regression analyses revealed that the serum levels of CEA and CA-125 and multiple liver metastases were independent risk factors for EHMs. Additionally, we recruited 190 patients with CRLMs from one of the hospitals as the validation set. The nomogram model achieved stable and accurate prediction results in the training and validation sets (AUC = 0.768 and 0.733), and was significantly superior to CEA and CA19-9. Moreover, the sensitivity and specificity of ¹⁸F-FDG PET/CT for the diagnosis of EHMs were 100% and 88%, respectively. Conclusions: We constructed and validated a nomogram on predicting the risk of EHMs in patients with CRLMs, which can guide clinicians to selective application of ¹⁸F-FDG PET/CT.

2024-11-05·Blood

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

作者: Zhu, Huanling ; Zhang, Yi ; Suo, Shanshan ; Jiang, Zhongxing ; Zhang, Jin ; Li, Xin ; Du, Xin ; Xu, Na ; Li, Yarong ; Zhou, Hu ; Hong, Mei ; Yang, Linhua ; Wang, Jishi ; Jing, Hongmei ; Zhou, ZePing ; Zhang, Feng ; He, Aili ; Xiao, Zhijian ; Jin, Chenghao ; Liu, Lin ; Xu, Yajing ; Gao, Sujun ; Chen, Yuqing ; Liu, Qingchi ; He, Guangsheng ; Jiang, Qian ; Li, Yan ; Jin, Jie ; Wu, Wen ; Zheng, Cuiping ; Zhuang, Junling ; Yue, Lingling ; Wu, Dengshu

Background: Myelofibrosis clinical manifestations typically include significant splenomegaly, high symptom burden and severe anemia. A phase III study (ZGJAK016) of gecacitinib (also known as jaktinib) met its primary endpoint, demonstrating 64.8% patients with a spleen volume reduction of ≥35% from baseline at week 24, along with favorable benefits in symptoms and anemia (presented at the European Hematology Association Hybrid Congress 2024). Herein, we present additional efficacy data that complement the positive findings from the ZGJAK016 study.Methods: A total of 105 myelofibrosis patients were included in the study (71 patients were randomized to gecacitinib and 34 to hydroxyurea). Key endpoints included changes in spleen length assessed by palpation, individual symptom score improvements, and transfusion independence rate. Transfusion independence was defined as not requiring red blood cell transfusion (except in cases of clinically overt bleeding) for ≥12 weeks, with hemoglobin ≥80 g/L.Results: Baseline characteristics were similar between treatment groups. The median spleen lengths were 15.0 cm and 13.3 cm in the gecacitinib and hydroxyurea groups. The median total symptom scores were 20.0 points and 19.0 points, respectively. A total of 77 (73.3%) symptomatic patients had a baseline total symptom score of ≥10 points (50 [70.4%] in the gecacitinib group and 27 [79.4%] in the hydroxyurea group). A lower proportion of patients in the gecacitinib group were transfusion-independent at baseline compared to hydroxyurea (70.4% vs. 76.5%).At Week 2, mean percentage changes from baseline in spleen length were -25.1% and -6.4% in the gecacitinib and hydroxyurea groups, with a higher proportion of patients achieving in a ≥50% decrease in palpable spleen length in the gecacitinib than in the hydroxyurea group (17.4% vs. 0, respectively).84.5% for gecacitinib and 61.8% for hydroxyurea achieved a ≥50% total symptom score reduction from baseline at any time (p = 0.0109). At Week 24, significant symptom improvement was observed in the gecacitinib group for each individual item, with mean percentage changes from baseline exceeding 50% in almost all cases (fatigue: -52.5%; early satiety: -59.7%; abdominal discomfort: -62%; inactivity: -39.6%; problems with concentration: -44.7%; night sweats: -87.7%; fever: -59.8%; weight loss: -87.6%; itching: -65.1%; and bone pain: -50.6%). In the symptomatic population, patients treated with gecacitinib showed higher rates of symptom improvement-defined as a decrease of at least 2 points-compared to those who received hydroxyurea in most individual items. This was particularly notable in night sweats (69.4% vs. 38.5%).Transfusion independence rates at Week 24 were achieved by 60.6% of 71 patients in the gecacitinib group and 38.2% of 34 in the hydroxyurea group, with a rate difference of 22.8% (95% CI, 3.1% to 42.5%; p = 0.0288). A steady increase in mean hemoglobin levels over time has been observed in patients with a baseline level of less than 100 g/L.Conclusions: The findings indicate that gecacitinib not only reaffirms its high efficacy in splenic size reduction but also demonstrates a rapid onset of action. In terms of symptom improvement, it significantly alleviated a range of symptoms, particularly in symptomatic patients. Regarding anemia, gecacitinib enhanced transfusion independence as evidenced by a higher transfusion independence rate at Week 24 compared to hydroxyurea, with comparable baseline characteristics. The ZGJAK016 study validates the critical role of gecacitinib in addressing the core treatment needs of myelofibrosis patients.

100 项与 Henan Provincial Cancer Hospital 相关的药物交易

登录后查看更多信息

100 项与 Henan Provincial Cancer Hospital 相关的转化医学

登录后查看更多信息